Irinotecan

Generic Name
Irinotecan
Brand Names
Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
Drug Type
Small Molecule
Chemical Formula
C33H38N4O6
CAS Number
97682-44-5
Unique Ingredient Identifier
7673326042
Background

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
Associated Therapies
-
Clinical Trials
Related News

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

First Posted Date
2019-10-28
Last Posted Date
2024-08-07
Lead Sponsor
University of Nebraska
Target Recruit Count
11
Registration Number
NCT04141995
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

First Posted Date
2019-10-07
Last Posted Date
2024-02-07
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
22
Registration Number
NCT04117945
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

MedStar Georgetown University Hospital, Washington, District of Columbia, United States

and more 12 locations

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

First Posted Date
2019-10-01
Last Posted Date
2023-08-14
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
42
Registration Number
NCT04109924
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

and more 1 locations

Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen

First Posted Date
2019-09-24
Last Posted Date
2019-11-05
Lead Sponsor
Fudan University
Target Recruit Count
126
Registration Number
NCT04101929
Locations
🇨🇳

Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China

CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC

First Posted Date
2019-09-20
Last Posted Date
2019-10-31
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
112
Registration Number
NCT04097444
Locations
🇯🇵

Ac Medical Inc., Chuo Ku, Tokyo, Japan

Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

First Posted Date
2019-09-19
Last Posted Date
2024-02-26
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
455
Registration Number
NCT04094688
Locations
🇺🇸

Los Angeles County-USC Medical Center, Los Angeles, California, United States

🇺🇸

Greater Baltimore Medical Center, Baltimore, Maryland, United States

🇺🇸

Sinai Hospital of Baltimore, Baltimore, Maryland, United States

and more 1024 locations

A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

First Posted Date
2019-09-19
Last Posted Date
2024-10-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
21
Registration Number
NCT04095221
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

First Posted Date
2019-08-30
Last Posted Date
2024-02-02
Lead Sponsor
University of California, Irvine
Target Recruit Count
20
Registration Number
NCT04074343
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States

🇺🇸

UC Davis Comprehensive Cancer Center, Sacramento, California, United States

Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients

First Posted Date
2019-08-28
Last Posted Date
2020-07-31
Lead Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Target Recruit Count
70
Registration Number
NCT04072198
Locations
🇮🇹

Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy

🇮🇹

Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy

🇮🇹

AUSL/IRCCS di Reggio Emilia, Reggio Emilia, Italy

and more 5 locations

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

First Posted Date
2019-08-28
Last Posted Date
2023-08-09
Lead Sponsor
Mayo Clinic
Target Recruit Count
28
Registration Number
NCT04072445
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy